Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

s one death in the q14d schedule due to renal failure from dehydration, possibly related to treatment. About Ovarian CancerNearly all ovarian cancers will become resistant or refractory to platinum-based therapy over time.  Ovarian cancer is the fifth leading cause of cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.(2)  Approximately 22,000 new cases of ovarian cancer will be diagnosed and 15,000 deaths are expected to be caused by ovarian cancer in the United States this year.(2)  Initial response rates to treatment with platinum-based agents can be as high as 80 percent, but most patients recur.  Treatment options following relapse are limited and overall long-term survival among ovarian cancer patients has not changed significantly in nearly 40 years.(3)  Agents currently approved by the U.S. Food & Drug Administration to treat women with platinum-resistant ovarian cancer have modest overall response rates of between 6.5 to 13.8 percent.(4,5)

About NKTR-102 Nektar is developing NKTR-102, a next-generation topoisomerase I inhibitor with reduced peak concentrations and a continuous concentration profile.  NKTR-102 was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.  

In addition to the fully-enrolled Phase 2 studies in platinum-refractory/resistant ovarian cancer and metastatic breast cancer, NKTR-102 is also being tested in a separate Phase 2 clinical trial in patients with second-line colorectal cancer and a Phase 1 clinical trial evaluating NKTR-102 in combination with 5-FU therapy.  An expansion arm of the Phase 2 study of single-agent NKTR-102 in platinum-refractory/resistant ovarian cancer in women who failed prior Doxil therapy is also currently enrolling.  A Phase 3 study of single-agent NKTR-102 is
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw ... with accompanying instrumentation to place and insert the screw ... soft tissue (e.g. ligament) repair or reconstruction as it ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... 2009 Convention -- When Shawnae Jebbia won the Miss USA ... career. She appeared at events throughout the world, worked as ... world unexpectedly changed when she was diagnosed with hearing loss. ... had a difficult time understanding and accepting the sudden hearing ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ), a leading provider ... medical device and related industries, announced today results for the ... Unless otherwise noted, all comparative numbers refer to changes from ... , Financial highlights for the third quarter of 2009: ...
Cached Medicine Technology:Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3ERT Reports Third Quarter 2009 Results 2ERT Reports Third Quarter 2009 Results 3ERT Reports Third Quarter 2009 Results 4ERT Reports Third Quarter 2009 Results 5ERT Reports Third Quarter 2009 Results 6ERT Reports Third Quarter 2009 Results 7ERT Reports Third Quarter 2009 Results 8ERT Reports Third Quarter 2009 Results 9ERT Reports Third Quarter 2009 Results 10ERT Reports Third Quarter 2009 Results 11ERT Reports Third Quarter 2009 Results 12ERT Reports Third Quarter 2009 Results 13
(Date:7/9/2014)... a reputation for being highly toxic, but when used in ... found to offer potential health benefits in a range of ... new compound (AP39), designed and made at the University of ... delivery of very small amounts of the substance to the ... Exeter have already found that the compound protects mitochondria ...
(Date:7/9/2014)... liver is one of the most important organs in ... we utilize our food properly this is its ... from our organism this is its detoxification function. ... unhealthy food all damage the liver. The resulting diseased ... cirrhoses, and life-threatening liver failure. According to the German ...
(Date:7/9/2014)... labels handed out by pharmacists may be misread ... according to new research by the University of ... Blind)., The study, published recently in the ... prescription medications dispensed by pharmacies do not consistently ... simply following recommended guidelines for font size, use ...
(Date:7/9/2014)... , , , , , ... , , , , ... assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... , ... , , , , , ... , , , , , , ...
(Date:7/9/2014)... The occurrence of allergic diseases has risen dramatically in ... are less exposed to microorganisms and have fewer infections ... system. , A study by researchers at Sahlgrenska Academy, ... three to examine maturation of the immune system in ... in rural areas of the Vstra Gtaland Region, half ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... , PORTLAND, Ore., July 29 While Congress debates ... its work to engage consumers to transform health care from the ... System - Engaging Consumers to Create Value-Driven Health Care," designed for ... and from Healthcare Marketing Report,s Annual Healthcare Advertising Awards. An interactive ...
... Death risk only 0.3 percent, chances of serious complications ... For those considering bariatric surgery to combat significant obesity, ... be much lower than what has previously been reported. ... surgery and laparoscopic adjustable gastric banding (lap-band surgery), found ...
... , , ST. LOUIS, July 29 ... quarter net income from continuing operations of $192.0 million, or $0.74 ... related to the previously announced acquisition of WellPoint,s pharmacy benefit management ... $0.76 for the same period last year. These earnings for the ...
... , , , SAN DIEGO, ... medical device company focused on developing products for minimally disruptive surgical ... of Finance and Investor Relations, is scheduled to present at the ... Hotel in New York, New York, on Wednesday, August 5, 2009, ...
... , COLUMBUS, Ohio, July 29 Roxane ... Drug Application (ANDA) for Risperidone Oral Solution, 1mg/mL by the ... 30mL bottles for immediate shipment to wholesalers and pharmacies nationwide. ... 1mg/mL are AA rated to RISPERDAL(R) (risperidone) oral solution. Annual ...
... , WASHINGTON, July 29 Three of the ... by supporting the Obama health-care plan, which would foster a ... sex education, euthanasia and eugenics. , , ... , , Catholic Charities USA, the Society ...
Cached Medicine News:Health News:Regence Wins Awards for Consumer Appeal to Transform Health Care 2Health News:Study Finds Weight-Loss Surgery Safer Than Thought 2Health News:Study Finds Weight-Loss Surgery Safer Than Thought 3Health News:Express Scripts Reports Strong Second Quarter Earnings 2Health News:Express Scripts Reports Strong Second Quarter Earnings 3Health News:Express Scripts Reports Strong Second Quarter Earnings 4Health News:Express Scripts Reports Strong Second Quarter Earnings 5Health News:Express Scripts Reports Strong Second Quarter Earnings 6Health News:Express Scripts Reports Strong Second Quarter Earnings 7Health News:Express Scripts Reports Strong Second Quarter Earnings 8Health News:Express Scripts Reports Strong Second Quarter Earnings 9Health News:Express Scripts Reports Strong Second Quarter Earnings 10Health News:Express Scripts Reports Strong Second Quarter Earnings 11Health News:Express Scripts Reports Strong Second Quarter Earnings 12Health News:Express Scripts Reports Strong Second Quarter Earnings 13Health News:Express Scripts Reports Strong Second Quarter Earnings 14Health News:NuVasive to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference 2Health News:NuVasive to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference 3Health News:Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL 2Health News:Catholic Charities, Vincent De Paul Society Supporting Abortion-Providing Healthcare Plan, Says ALL 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: